Nabi ready for a deal after NicVAX hits endpoint

Shares of Nabi Pharmaceuticals surged 18 percent this morning after researchers announced that its NicVAX vaccine hit its primary goal--eight weeks of continuous abstinence by a statistically significant number of smokers--in a mid-stage trial. The company said the "top 30 percent of antibody responders (61 of the total 201 patients receiving drug) were examined in detail. A statistically significant number of these patients...showed continuous abstinence between weeks 19-26 compared to only 13 percent for the 100 patients receiving placebo." The trial enrolled 301 heavy smokers for the test, and Nabi officials say the results sets the stage for a late-stage trial and a partnership agreement.

"We believe NicVAX is now well positioned to enter Phase III pivotal trials and to secure a strategic partner," interim President and CEO Leslie Hudson said in a statement.

- see this release on the new data

Related Articles:
FDA panel votes in favor of Nabi therapy. Report
Nabi CEO walks after hedge fund balks. Report
Nabi vows to push ahead with vaccine work. Report
Nabi to close European operations. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.